An observational study in Peripheral Arterial Disease, sponsored by CID S.p.A.. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by CID S.p.A. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 120 studies in Peripheral Arterial Disease with a site in France — 21 open to participants now, 27 under way, 4 of them phase 3. Peripheral Arterial Disease · France.
Among the 120 studies in Peripheral Arterial Disease with a site in France, this one is the 50th largest by enrollment of the 54 observational ones that give a count, is one of 6 that started in 2023, is one of 54 observational ones, and was the 102nd registered.
1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.
Browse Peripheral Arterial Disease studies →21 of the 120 studies in Peripheral Arterial Disease with a site in France are open now. Recruiting first, the newest first:
Poitiers University Hospital · Sites in France
Ages 18+
Intervascular · Sites in France, United States, Belgium and 1 more country
Ages 18+
Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer · Sites in France
Ages 18+
Eli Lilly and Company · Sites in France, United States, Argentina and 15 more countries
Ages 18+
Atrium Medical Corporation · Sites in France, United States
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
120 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 13 · Phase 4 7
First in 2002; this study’s year is marked. 6 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 32 is below the median of 187 across 399 observational studies indexed under Peripheral Arterial Disease.
Median enrollment 106 across the 66 interventional studies, 298 across the 54 observational. Of the 82 that completed or were terminated, 12 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 120 have an industry lead sponsor. The 10 most frequent:
CID S.p.A. is the lead sponsor of 7 studies on the registry; none are open to participants now.
CID S.p.A. has 4 studies filed under Peripheral Arterial Disease — fewer than ten, so there is no comparison to draw.
4 of the studies in Peripheral Arterial Disease with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07283289Centre Hospitalier Intercommunal de Toulon La Seyne sur MerPrevalence of Obstructive Sleep Apnea in Patients With Peripheral Arterial Occlusive Disease | 2026-11 |
| NCT05055297M.A. Med Alliance S.A.SELUTION4BTK Trial | 2027-06-01 |
| NCT07322913IntervascularIntervascular Post-Market Clinical Follow-Up (PMCF) Registry | 2027-07 |
| NCT07181434Poitiers University HospitalImpact of Virtual Reality on Patient Pain During Lower Limb Revascularization Via Endovascular Surgery Under Local Anesthesia With Sedation | 2027-09-03 |
Add all 4 to your calendar (.ics) → With an account.
Among the 120 studies in Peripheral Arterial Disease with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The Inperia Advance Carbostent™ is a CE-marked infra-popliteal stent for treatment of infra-popliteal artery stenosis. The aim of this post-market retrospective study protocl P32203 is to collect clinical data of patients treated with Inperia Advance for the treatment of infra-popliteal artery stenosis in routine clinical practice. In order to obtain long-term follow-up data, the data collection will be limited to patients that have been treated with the device at least 12 months prior to the study start.
The objective of this post-market study is to systematically collect retrospective clinical data on the implantable medical device Inperia Advance in the daily clinical practice in an unselected population treated within the intended use. Data will be collected via medical chart review in anonymous form to assess the safety and efficacy of Inperia Adavance. The Inperia Advance Carbostent™ is a CE-marked infra-popliteal stent for treatment of infra-popliteal artery stenosis.
Patients implanted with at least one Inperia Advance stent for treatment of infra-popliteal artery stenosis, at least 12 months prior to the start date of the retrospective data collection.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with infra-popliteal artery stenosis implanted with at least one Inperia Advance device
Rate of Major Adverse Events (MAE)
Composite endpoint of all causes of death, unplanned target limb major amputation and/or clinically indicated target lesion revascularization (TLR)
Time frame: 12 months
Primary patency
Primary patency is defined as absence of clinically-driven target lesion revascularization or binary restenosis. Binary restenosis is defined as a peak systolic velocity ratio (PSVR) \>2.4 (Duplex Ultrasound evaluation)
Time frame: 6 months and 12 months
Limb-salvage rate (LSR)
Limb-salvage rate (LSR) is defined as rate of patients free from major amputation. Major amputation is defined as at or above ankle, as opposed to minor amputation being at or below metatarsus preserving functionality of foot
Time frame: 6 months and 12 months
Secondary patency
Patency following successful target lesion revascularization (TLR)
Time frame: 6 months and 12 months or latest patency data available
Death
Death within 30 days of the index procedure
Time frame: 30 days
Clinically driven Target Lesion Revascularization
Clinically driven Target Lesion Revascularization
Time frame: 6 months and 12 months
Target limb ischemia
Target limb ischemia requiring surgical intervention or surgical repair of target vessel rate
Time frame: 6 months and 12 months
Rutherford category measurement
Rutherford category measurement
Time frame: pretreatment, 6 months and 12 months
Evaluation of Serious Adverse Events (SAEs)
Evaluation of Serious Adverse Events (SAEs)
Time frame: 6 months and 12 months
Acute success (device and procedural) within discharge
Clinical device success defined as successful delivery and deployment of the stent(s) at the intended target lesion (this includes successful delivery and deployment of multiple stents) and final residual stenosis of the target lesion minor or equal to 30%, assessed by visual estimation and clinical device success without the occurrence of MAE during the hospital stay
Time frame: 24/72 hours
Plan to share: No
Ran from Mar 2023 to primary completion in Jun 2023, 2 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: start Feb 2023 → Mar 2023 and completion Jul 2023 → Jun 2023.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
CID S.p.A.